FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jennifer Lofland

Research Profile

Disorders

Migraine Disorders

Activities & Behaviors

Chemicals & Drugs

Geographic Areas

Concepts & Ideas

Co-author Network

Publications

TOP 3
Joshua J Gagne; Brian Leas; Jennifer H Lofland; Neil I Goldfarb; Frederick G Freitag; Stephen Silberstein
Quality of care measures for migraine: a comprehensive review.
Jennifer H Lofland; Joshua J Gagne; Laura T Pizzi; Marcia F T Rupnow; Stephen D Silberstein
Impact of topiramate migraine prophylaxis on workplace productivity: results from two US randomized, double-blind, placebo-controlled, multicenter trials.
Jennifer H Lofland; Kevin D Frick
Workplace absenteeism and aspects of access to health care for individuals with migraine headache.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jennifer Lofland (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Joshua J Gagne; Brian Leas; Jennifer H Lofland; Neil I Goldfarb; Frederick G Freitag; Stephen Silberstein
Quality of care measures for migraine: a comprehensive review.
Disease management : DM 2007;10(3):138-46.
2007: Jennifer H Lofland; Joshua J Gagne; Laura T Pizzi; Marcia F T Rupnow; Stephen D Silberstein
Impact of topiramate migraine prophylaxis on workplace productivity: results from two US randomized, double-blind, placebo-controlled, multicenter trials.
Journal of occupational and environmental medicine / American College of Occupational and Environmental Medicine 2007;49(3):252-7.
2006: Jennifer H Lofland; Kevin D Frick
Workplace absenteeism and aspects of access to health care for individuals with migraine headache.
Headache 2006;46(4):563-76.
2006: Jennifer H Lofland; Kevin D Frick
Effect of health insurance on workplace absenteeism in the U.S. workforce.
Journal of occupational and environmental medicine / American College of Occupational and Environmental Medicine 2006;48(1):13-21.
2005: Jennifer H Lofland; David B Nash
Oral serotonin receptor agonists: a review of their cost effectiveness in migraine.
PharmacoEconomics 2005;23(3):259-74.
2004: Vittorio Maio; Jennifer H Lofland
Outcome measures for pharmacoeconomics education.
PharmacoEconomics 2004;22(8):549-50.
2004: Jennifer H Lofland; Laura T Pizzi; Kevin D Frick
A review of health-related workplace productivity loss instruments.
PharmacoEconomics 2004;22(3):165-84.
2003: Ronald Loeppke; Pamela A Hymel; Jennifer H Lofland; Laura T Pizzi; Doris Konicki; George W Anstadt; Cathy Baase; Joseph Fortuna; Ted Scharf
Health-related workplace productivity measurement: general and migraine-specific recommendations from the ACOEM Expert Panel.
Journal of occupational and environmental medicine / American College of Occupational and Environmental Medicine 2003;45(4):349-59.
2002: Mary Lou Chatterton; Jennifer H Lofland; Aaron Shechter; Walter Scott Curtice; X Henry Hu; Jeffrey Lenow; Stanton N Smullens; David B Nash; Stephen D Silberstein
Reliability and validity of the migraine therapy assessment questionnaire.
Headache 2002;42(10):1006-15.
2002: Jennifer H Lofland; Kevin D Frick
Publicly available US national surveys that capture lost productivity.
Expert review of pharmacoeconomics & outcomes research 2002;2(5):485-94.
2001: Jennifer H Lofland; S S Kim; Alice S Batenhorst; N E Johnson; Mary Lou Chatterton; Roger K Cady; R Kaniecki; David B Nash
Cost-effectiveness and cost-benefit of sumatriptan in patients with migraine.
Mayo Clinic proceedings. Mayo Clinic 2001;76(11):1093-101.
2001: D M Meletiche; Jennifer H Lofland; William B Young
Quality-of-life differences between patients with episodic and transformed migraine.
Headache 2001;41(6):573-8.
2001: Jennifer H Lofland; J C Locklear; Kevin D Frick
Different approaches to valuing the lost productivity of patients with migraine.
PharmacoEconomics 2001;19(9):917-25.
2001: Vittorio Maio; T K Girts; Jennifer H Lofland; David B Nash
Pharmacoeconomic fellowships: the need for outcome measures.
PharmacoEconomics 2001;19(8):795-802.
2000: Jennifer H Lofland; John P O'Connor; Mary Lou Chatterton; Elizabeth D Moxey; LE Paddock; David B Nash; SA Desai
Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.
Clinical therapeutics 2000;22(11):1357-69.
2000: Jennifer H Lofland; M Schaffer; Neil I Goldfarb
Evaluating health-related quality of life: cost comparison of computerized touch-screen technology and traditional paper systems.
Pharmacotherapy 2000;20(11):1390-5.
1999: D M Meletiche; D Doshi; Jennifer H Lofland
Medical Outcomes Study Short Form 36: a possible source of utilities?
Clinical therapeutics 1999;21(11):2016-26; discussion 215.
1999: Jennifer H Lofland; N E Johnson; Alice S Batenhorst; David B Nash
Changes in resource use and outcomes for patients with migraine treated with sumatriptan: a managed care perspective.
Archives of internal medicine 1999;159(8):857-63.